Global Epilepsy Devices Market Research Report—Forecast till 2027

Global Epilepsy Devices Market Research Report—Forecast till 2027

$4450 – $6250

Global Epilepsy Devices Market anticipated record a significant CAGR of 6.56% during the review period of 2020 to 2027. Epilepsy is an incurable disease caused because of neurological complications and necessarily prevalent and repeatedly rising old age population.

SKU: MRFR210150 Category: Tag:

Description

Global Epilepsy Devices Market Research Report—Forecast till 2027

Market Overview
Global Epilepsy Devices Market anticipated record a significant CAGR of 6.56% during the review period of 2020 to 2027. Epilepsy is an incurable disease caused because of neurological complications and necessarily prevalent and repeatedly rising old age population. As per the Mayo Clinic (US), epilepsy is a central nervous system (neurological) disease in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. The global market growth is attributed to the increasing prevalence of epilepsy amongst the geriatric population, rising cases of brain injuries owing to road accidents, a large patient pool suffering from neurological disorders, and growing research funding in epilepsy.
The global Epilepsy devices market is expected to witness a healthy market owing to the highest market value of USD 551.2 Million in 2019. The expansion of the global epilepsy devices market is driven by a large patient pool suffering from neurological disorders. As per the WHO, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. The inherent and expanding demand for novel therapies to solve epilepsy-related problems is boosting the manufacturers to develop innovative products.

Market Segmentation
Global Epilepsy Devices Market has been categorized into Product Type, Technology, Seizure Detection and Prediction Devices, and End-Use.
In terms of product type, the global epilepsy devices market is classified into wearable devices, conventional devices, and implantable devices. The wearable devices segment is further classified into watches, bracelets, camera devices, mattress devices, anti-suffocation pillows, and others. Based on technology type, the global epilepsy devices market has been divided into vagus nerve stimulation, responsive neurostimulation, deep brain stimulation, and accelerometry.
By seizure detection and prediction devices, the global market has been segmented into electroencephalogram, intracranial EEG, surface electromyography, electrodermal activity, electrocardiography, video detection systems, implanted advisory systems, and others. Based on the end-user segment, the global epilepsy devices market has been segregated into hospitals & clinics, neurology centers, home care settings, and others.
Regional Analysis
Geographically, the Global Epilepsy Devices Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global epilepsy devices market due to a large number of companies operating in the region, government regulations, and the increasing healthcare expenditure in the region. The region accounted for a considerable market share of 40.3% in the global epilepsy devices market.
Europe is expected to register the second largest market of the global epilepsy devices market during the forecast period, due to the availability of reimbursement, rising geriatric population prone to epilepsy, and technological advancements in therapeutic devices. Additionally, the presence of highly developed healthcare infrastructure and the research funds from governmental organizations is expected to have a positive impact on the European epilepsy devices market.
Asia-Pacific is expected to register the fastest growing market owing to the increasing population, rising number of patients suffering from epilepsy, the growing awareness about the available treatment options, and strategic decisions by key players operating in the region. The market for epilepsy devices is increasing in the Middle East and Africa (MEA) owing to rising product launches in the region.
Major Players
The Key Players in the Global Epilepsy Devices Market are Boston Scientific Corporation, Medpage Ltd. (Easylink UK), Cerbomed GmbH (TVNS Technologies GmbH), Liva Nova (Cyberonics), Compumedics, Nihon Kohden, MC10, Empatica, Inc, Medtronic Plc, Neuropace, Inc, and Natus Medical Incorporated.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 OVERVIEW 17 1.2 MARKET ATTRACTIVENESS ANALYSIS 18 1.2.1 GLOBAL EPILEPSY DEVICES MARKET, BY PRODUCT TYPE 18 1.2.1.1 GLOBAL EPILEPSY DEVICES MARKET, BY WEARABLE DEVICES 19 1.2.2 GLOBAL EPILEPSY DEVICES MARKET, BY TECHNOLOGY 20 1.2.3 GLOBAL EPILEPSY DEVICES MARKET, BY SEIZURE DETECTION AND PREDICTION DEVICES 21 1.2.4 GLOBAL EPILEPSY DEVICES MARKET, BY END USE 22 1.2.5 GLOBAL EPILEPSY DEVICES MARKET, BY REGION 23 2 MARKET INTRODUCTION 2.1 SCOPE OF THE STUDY 24 2.2 RESEARCH OBJECTIVE 24 2.3 MARKET STRUCTURE 25 3 RESEARCH METHODOLOGY 3.1 RESEARCH PROCESS 26 3.2 PRIMARY RESEARCH 27 3.3 SECONDARY RESEARCH 28 3.4 MARKET SIZE ESTIMATION 28 3.5 FORECAST MODEL 30 3.6 LIST OF ASSUMPTIONS & LIMITATIONS 31 4 MARKET DYNAMICS 4.1 INTRODUCTION 32 4.2 DRIVERS 33 4.2.1 RISING PREVALENCE OF EPILEPSY AMONGST THE GERIATRIC POPULATION 33 4.2.2 INCREASING CASES OF BRAIN INJURIES DUE TO ROAD ACCIDENTS 33 4.2.3 RISING NEUROLOGICAL DISORDERS 33 4.2.4 INCREASING RESEARCH FUNDING IN EPILEPSY 34 4.2.5 DRIVERS IMPACT ANALYSIS 34 4.3 RESTRAINTS 35 4.3.1 LOSS OF PATENT PROTECTION FOR BRANDED DRUGS 35 4.3.2 HIGH COSTS ASSOCIATED WITH THE TREATMENT OF EPILEPSY 35 4.3.3 RESTRAINTS IMPACT ANALYSIS 35 4.4 OPPORTUNITIES 36 4.4.1 ENTERING DEVELOPING ECONOMIES 36 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN 37 5.1.1 RESEARCH & DEVELOPMENT AND DESIGNING 37 5.1.2 MANUFACTURING 37 5.1.3 DISTRIBUTION & SALES 37 5.1.4 POST-SALES SERVICES 38 5.2 PORTER’S FIVE FORCES MODEL 38 5.2.1 THREAT OF NEW ENTRANTS 38 5.2.2 BARGAINING POWER OF SUPPLIERS 39 5.2.3 THREAT OF SUBSTITUTES 39 5.2.4 BARGAINING POWER OF BUYERS 39 5.2.5 INTENSITY OF RIVALRY 39 5.3 IMPACT OF COVID-19 ON THE GLOBAL EPILEPSY DEVICES MARKET 39 5.3.1 OVERVIEW 39 5.3.2 IMPACT ON SUPPLY CHAIN 40 5.3.3 IMPACT ON PRODUCTION/MANUFACTURERS 40 5.3.4 IMPACT ON REGIONS 40 5.3.5 IMPACT ON DEMAND 40 6 GLOBAL EPILEPSY DEVICES MARKET, BY PRODUCT TYPE 6.1 INTRODUCTION 41 6.2 WEARABLE DEVICES 42 6.2.1 WATCHES 43 6.2.2 BRACELETS 43 6.2.3 CAMERA DEVICES 43 6.2.4 MATTRESS DEVICES 44 6.2.5 ANTI-SUFFOCATION PILLOWS 44 6.2.6 OTHERS 44 6.3 CONVENTIONAL DEVICES 45 6.4 IMPLANTABLE DEVICES 45 7 GLOBAL EPILEPSY DEVICES MARKET BY TECHNOLOGY 7.1 OVERVIEW 46 7.2 VAGUS NERVE STIMULATION (VNS) 47 7.3 RESPONSIVE NEUROSTIMULATION 47 7.4 DEEP BRAIN STIMULATION 48 7.5 ACCELEROMETRY 48 8 GLOBAL EPILEPSY DEVICES MARKET, BY SEIZURE DETECTION AND PREDICTION DEVICES 8.1 OVERVIEW 49 8.2 ELECTROENCEPHALOGRAM (EEG) 50 8.3 INTRACRANIAL EEG 51 8.4 SURFACE ELECTROMYOGRAPHY (SEMG) 51 8.5 ELECTRODERMAL ACTIVITY (EDA) 51 8.6 ELECTROCARDIOGRAPHY (EKG) 52 8.7 VIDEO DETECTION SYSTEMS 52 8.8 IMPLANTED ADVISORY SYSTEMS 53 8.9 OTHERS 53 9 GLOBAL EPILEPSY DEVICES MARKET, BY END USE 9.1 OVERVIEW 54 9.2 HOSPITALS & CLINICS 55 9.3 NEUROLOGY CENTERS 55 9.4 HOME CARE SETTINGS 56 9.5 OTHERS 56 10 GLOBAL EPILEPSY DEVICES MARKET, BY REGION 10.1 INTRODUCTION 57 10.2 AMERICAS 58 10.2.1 NORTH AMERICA 61 10.2.1.1 US 64 10.2.1.2 CANADA 66 10.2.2 LATIN AMERICA 68 10.3 EUROPE 70 10.3.1 WESTERN EUROPE 73 10.3.1.1 GERMANY 76 10.3.1.2 FRANCE 78 10.3.1.3 UK 80 10.3.1.4 ITALY 82 10.3.1.5 SPAIN 84 10.3.1.6 REST OF WESTERN EUROPE 86 10.3.2 EASTERN EUROPE 88   10.4 ASIA-PACIFIC 90 10.4.1 CHINA 93 10.4.2 INDIA 95 10.4.3 JAPAN 97 10.4.4 AUSTRALIA 99 10.4.5 SOUTH KOREA 101 10.4.6 REST OF ASIA-PACIFIC 103 10.5 MIDDLE EAST & AFRICA 105 10.5.1 MIDDLE EAST 108 10.5.2 AFRICA 110 11 COMPETITIVE LANDSCAPE 11.1 COMPETITIVE OVERVIEW 112 11.2 COMPETITOR DASHBOARD 112 11.3 MARKET SHARE ANALYSIS 113 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL EPILEPSY DEVICES MARKET 114 11.5 COMPETITIVE BENCHMARKING 115 11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPILEPSY DEVICES MARKET 116 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 117 11.7.1 PRODUCT DEVELOPMENTS/LAUNCHES 117 11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES 118 11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 118 11.8.1 SALES & OPERATING INCOME 118 11.8.2 R&D EXPENDITURE 119 12 COMPANY PROFILES 12.1 BOSTON SCIENTIFIC CORPORATION 120 12.1.1 COMPANY OVERVIEW 120 12.1.2 FINANCIAL OVERVIEW 121 12.1.3 PRODUCTS/SERVICES OFFERED 122 12.1.4 KEY DEVELOPMENTS 122 12.1.5 SWOT ANALYSIS 123 12.1.6 KEY STRATEGIES 123 12.2 MEDPAGE LTD. (EASYLINK UK) 124 12.2.1 COMPANY OVERVIEW 124 12.2.2 FINANCIAL OVERVIEW 124 12.2.3 PRODUCTS/SERVICES OFFERED 124 12.2.4 KEY DEVELOPMENTS 125 12.2.5 SWOT ANALYSIS 125 12.2.6 KEY STRATEGIES 125 12.3 CERBOMED GMBH (TVNS TECHNOLOGIES GMBH) 126 12.3.1 COMPANY OVERVIEW 126 12.3.2 FINANCIAL OVERVIEW 126 12.3.3 PRODUCTS/SERVICES OFFERED 126 12.3.4 KEY DEVELOPMENTS 126 12.3.5 SWOT ANALYSIS 127 12.3.6 KEY STRATEGIES 127 12.4 LIVA NOVA (CYBERONICS) 128 12.4.1 COMPANY OVERVIEW 128 12.4.2 FINANCIAL OVERVIEW 129 12.4.3 PRODUCTS/SERVICES OFFERED 129 12.4.4 KEY DEVELOPMENTS 130 12.4.5 SWOT ANALYSIS 130 12.4.6 KEY STRATEGIES 130 12.5 COMPUMEDICS 131 12.5.1 COMPANY OVERVIEW 131 12.5.2 FINANCIAL OVERVIEW 131 12.5.3 PRODUCTS/SERVICES OFFERED 132 12.5.4 KEY DEVELOPMENTS 132 12.5.5 SWOT ANALYSIS 133 12.5.6 KEY STRATEGIES 133 12.6 NIHON KOHDEN 134 12.6.1 COMPANY OVERVIEW 134 12.6.2 FINANCIAL OVERVIEW 135 12.6.3 PRODUCTS/SERVICES OFFERED 136 12.6.4 KEY DEVELOPMENTS 136 12.6.5 SWOT ANALYSIS 137 12.6.6 KEY STRATEGIES 137 12.7 MC10 138 12.7.1 COMPANY OVERVIEW 138 12.7.2 FINANCIAL OVERVIEW 138 12.7.3 PRODUCTS/SERVICES OFFERED 138 12.7.4 KEY DEVELOPMENTS 138 12.7.5 SWOT ANALYSIS 139 12.7.6 KEY STRATEGIES 139   12.8 EMPATICA, INC. 140 12.8.1 COMPANY OVERVIEW 140 12.8.2 FINANCIAL OVERVIEW 140 12.8.3 PRODUCTS/SERVICES OFFERED 140 12.8.4 KEY DEVELOPMENTS 140 12.8.5 SWOT ANALYSIS 141 12.8.6 KEY STRATEGIES 141 12.9 MEDTRONIC PLC 142 12.9.1 COMPANY OVERVIEW 142 12.9.2 FINANCIAL OVERVIEW 143 12.9.3 PRODUCTS/SERVICES OFFERED 143 12.9.4 KEY DEVELOPMENTS 144 12.9.5 SWOT ANALYSIS 144 12.9.6 KEY STRATEGIES 144 12.10 NEUROPACE, INC. 145 12.10.1 COMPANY OVERVIEW 145 12.10.2 FINANCIAL OVERVIEW 145 12.10.3 PRODUCTS/SERVICES OFFERED 145 12.10.4 KEY DEVELOPMENTS 145 12.10.5 SWOT ANALYSIS 146 12.10.6 KEY STRATEGIES 146 12.11 NATUS MEDICAL INCORPORATED 147 12.11.1 COMPANY OVERVIEW 147 12.11.2 FINANCIAL OVERVIEW 148 12.11.3 PRODUCTS/SERVICES OFFERED 149 12.11.4 KEY DEVELOPMENTS 149 12.11.5 SWOT ANALYSIS 150 12.11.6 KEY STRATEGIES 150 13 APPENDIX 13.1 REFERENCES 151"

Related products